ERCC1 and non-small cell lung carcinoma: Previously, we also reported that ERCC1 expression estimated by immunohistochemistry was an independent prognostic factor in terms of both proression-free survival (PFS) and overall survival (OS) in patients with NSCLC relapse who had received platinum-based chemotherapy [16].